Telomir Pharmaceuticals (TELO) Accounts Payables (2022 - 2026)
Telomir Pharmaceuticals (TELO) posted Accounts Payables of $536769.0 for Q4 2025, up 62.97% sequentially from $329375.0 in Q3 2025, and down 8.64% YoY from $587536.0 in Q4 2024.
Telomir Pharmaceuticals (TELO) Accounts Payables (2022 - 2026) Analysis & Trends
Telomir Pharmaceuticals has reported Accounts Payables for 4 years, with the latest figure at $536769.0 in Q4 2025.
- Quarterly Accounts Payables fell 8.64% year-over-year to $536769.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $536769.0 (down 8.64% YoY) and the FY2025 annual result came in at $536769.0, down 8.64% from the prior year.
- Accounts Payables advanced to $536769.0 in Q4 2025 per TELO's latest filing, from $329375.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $707187.0 in Q4 2023 and troughed at $254956.0 in Q2 2025.
- A 4-year average of $475784.9 and a median of $492564.5 in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2025: Accounts Payables surged 74.95% in 2023, then plunged 35.26% in 2025.
- Over 4 years, Accounts Payables stood at $404221.0 in 2022, then jumped by 74.95% to $707187.0 in 2023, then declined by 16.92% to $587536.0 in 2024, then declined by 8.64% to $536769.0 in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $536769.0, $329375.0, and $254956.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Telomir Pharmaceuticals | 68.14 Mn | 68.14 Mn | - | 195,526.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 195,526.00 |
| Dec 31, 2025 | 536,769.00 |
| Sep 30, 2025 | 329,375.00 |
| Jun 30, 2025 | 254,956.00 |
| Mar 31, 2025 | 558,862.00 |
| Dec 31, 2024 | 587,536.00 |
| Sep 30, 2024 | 506,479.00 |
| Jun 30, 2024 | 393,814.00 |
| Mar 31, 2024 | 478,650.00 |
| Dec 31, 2023 | 707,187.00 |
| Dec 31, 2022 | 404,221.00 |